Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases

Mucormycosis has emerged as an increasingly important infection in oncology centres with high mortality, especially in severely immunocompromised patients. We carried out a retrospective study of 11 children with mucormycosis treated in seven French oncology‐haematology paediatric wards during the period from 1991 to 2011. Lichtheimia corymbifera and Mucor spp. were the predominant pathogens. Treatment regimens included antifungal therapy, reversal of underlying predisposing risk factors and surgical debridement. Although mucormycosis is associated with high mortality, this infection could be cured in eight of our cases of severely immunocompromised paediatric cancer patients.

[1]  J. Perfect,et al.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. , 2011, The Journal of antimicrobial chemotherapy.

[2]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  A. Attarbaschi,et al.  Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases , 2011, Mycoses.

[4]  D. Kontoyiannis,et al.  How I treat mucormycosis. , 2011, Blood.

[5]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[6]  T. Lion,et al.  Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients , 2010, Leukemia.

[7]  C. Junghanss,et al.  Invasive zygomycosis in patients with graft‐versus‐host disease after allogeneic stem cell transplantation , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  J. Willert,et al.  Zygomycetes Infections in Pediatric HematologyOncology Patients: A Case Series and Review of the Literature , 2009, Journal of pediatric hematology/oncology.

[9]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Samonis,et al.  Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  A. Symeonidis.  The role of iron and iron chelators in zygomycosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Walsh,et al.  Zygomycosis in Children: A Systematic Review and Analysis of Reported Cases , 2007, The Pediatric infectious disease journal.

[15]  Michael Weiss,et al.  A higher-level phylogenetic classification of the Fungi. , 2007, Mycological research.

[16]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Brad Spellberg,et al.  Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management , 2005, Clinical Microbiology Reviews.

[18]  L. Pagano,et al.  Mucormycosis in hematologic patients. , 2004, Haematologica.

[19]  M. Lichterfeld,et al.  Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. , 2003, American journal of clinical pathology.

[20]  J. Meis,et al.  In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.